Since EpCAM expression was shown to be downregulated in squamous cell carcinomas [10], whereas EGFR is frequently overexpressed in HNSCC [11], we hypothesized that the inclusion of both tumor–associated markers may increase sensitivity for the detection of CTCs, especially in tumors with an EMT phenotype displaying low or absent EpCAM expression. The gene discussed is EPCAM; the disease is neoplasm.